1-20 of 57
David M. Goldenberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Free
Jhanelle E. Gray, Rebecca S. Heist, Alexander N. Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles J. Schneider, Bryan J. Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius P. Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5711–5719.
https://doi.org/10.1158/1078-0432.CCR-17-0933
Published: 01 October 2017
View articletitled, Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Open the PDF for Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan in another window
Includes: Supplementary data
Journal Articles

Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer

Free
Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali A. Mostafa, David M. Goldenberg
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (13): 3405–3415.
https://doi.org/10.1158/1078-0432.CCR-16-2401
Published: 02 July 2017
View articletitled, Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer
Open the PDF for Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A32: Pretargeted immunoPET of CEA-expressing in intraperitoneal human colonic tumor xenografts in nude mice

Free
Rafke Schoffelen, Robert M. Sharkey, Gerben M. Franssen, David M. Goldenberg, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, Peter Laverman, Winette T.A. Graaf, Wim J.G. Oyen, Otto C. Boerman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7_Supplement): A32.
https://doi.org/10.1158/1078-0432.TCME10-A32
Published: 02 February 2016
View articletitled, Abstract A32: Pretargeted immunoPET of CEA-expressing in intraperitoneal human colonic tumor xenografts in nude mice
Journal Articles

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)

Free
Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5131–5138.
https://doi.org/10.1158/1078-0432.CCR-15-0670
Published: 12 November 2015
View articletitled, Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Open the PDF for Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan) in another window
Includes: Supplementary data
Journal Articles

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Free
Alexander N. Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Jr, Linda T. Vahdat, Sajeve S. Thomas, Serengulam V. Govindan, Pius P. Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3870–3878.
https://doi.org/10.1158/1078-0432.CCR-14-3321
Published: 31 August 2015
View articletitled, First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Open the PDF for First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies

Free
Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 347–356.
https://doi.org/10.1158/1078-0432.CCR-12-2046
Published: 16 January 2013
View articletitled, Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
Open the PDF for Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies in another window
Includes: Supplementary data
Journal Articles

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

Free
Seza A. Gulec, Steven J. Cohen, Kenneth L. Pennington, Lionel S. Zuckier, Ralph J. Hauke, Heather Horne, William A. Wegener, Nick Teoh, David V. Gold, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4091–4100.
https://doi.org/10.1158/1078-0432.CCR-10-2579
Published: 15 June 2011
View articletitled, Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
Open the PDF for Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial in another window
Journal Articles

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

Free
Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3157–3169.
https://doi.org/10.1158/1078-0432.CCR-10-2939
Published: 15 May 2011
View articletitled, Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Open the PDF for Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys in another window
Includes: Supplementary data
Journal Articles

CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates

Free
Serengulam V. Govindan, Thomas M. Cardillo, Sung-Ju Moon, Hans J. Hansen, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6052–6061.
https://doi.org/10.1158/1078-0432.CCR-09-0586
Published: 30 September 2009
View articletitled, CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
Open the PDF for CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates in another window
Journal Articles

Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines

Free
Rhona Stein, Mitchell R. Smith, Susan Chen, Maria Zalath, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2808–2817.
https://doi.org/10.1158/1078-0432.CCR-08-1953
Published: 15 April 2009
View articletitled, Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
Open the PDF for Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines in another window
Journal Articles

Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)

Free
M. Jules Mattes, Robert M. Sharkey, Habibe Karacay, Myron S. Czuczman, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6154–6160.
https://doi.org/10.1158/1078-0432.CCR-08-0404
Published: 30 September 2008
View articletitled, Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
Open the PDF for Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab) in another window
Journal Articles

PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma

Free
David V. Gold, Zarir Karanjawala, David E. Modrak, David M. Goldenberg, Ralph H. Hruban
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7380–7387.
https://doi.org/10.1158/1078-0432.CCR-07-1488
Published: 19 December 2007
View articletitled, PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
Open the PDF for PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma in another window
Journal Articles

A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies

Free
Pierre-Yves Brard, Habibe Karacay, Rhona Stein, Robert M. Sharkey, M. Jules Mattes, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5564s–5571s.
https://doi.org/10.1158/1078-0432.CCR-07-1204
Published: 17 September 2007
View articletitled, A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies
Open the PDF for A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies in another window
Journal Articles

Introduction to the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates

Free
David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5499s–5500s.
https://doi.org/10.1158/1078-0432.CCR-07-1226
Published: 17 September 2007
View articletitled, Introduction to the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates
Open the PDF for Introduction to the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates in another window
Journal Articles

The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity

Free
Chien-Hsing Chang, Edmund A. Rossi, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5586s–5591s.
https://doi.org/10.1158/1078-0432.CCR-07-1217
Published: 17 September 2007
View articletitled, The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity
Open the PDF for The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity in another window
Journal Articles

CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms

Free
Rhona Stein, M. Jules Mattes, Thomas M. Cardillo, Hans J. Hansen, Chien-Hsing Chang, Jack Burton, Serengulam Govindan, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5556s–5563s.
https://doi.org/10.1158/1078-0432.CCR-07-1167
Published: 17 September 2007
View articletitled, CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms
Open the PDF for CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms in another window
Journal Articles

Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update

Free
Robert M. Sharkey, Habibe Karacay, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5577s–5585s.
https://doi.org/10.1158/1078-0432.CCR-07-1087
Published: 17 September 2007
View articletitled, Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update
Open the PDF for Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update in another window
Journal Articles

Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors

Free
Dieter Moosmayer, Dietmar Berndorff, Chien-Hsing Chang, Robert M. Sharkey, Axel Rother, Sandra Borkowski, Edmund A. Rossi, William J. McBride, Thomas M. Cardillo, David M. Goldenberg, Ludger M. Dinkelborg
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5587–5595.
https://doi.org/10.1158/1078-0432.CCR-06-0210
Published: 25 September 2006
View articletitled, Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors
Open the PDF for Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors in another window
Journal Articles

Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft

Free
Habibe Karacay, Pierre-Yves Brard, Robert M. Sharkey, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride, Dan R. Ragland, Ivan D. Horak, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7879–7885.
https://doi.org/10.1158/1078-0432.CCR-05-1246
Published: 08 November 2005
View articletitled, Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft
Open the PDF for Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft in another window
Journal Articles

Pretargeting of Carcinoembryonic Antigen–Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen × Anti-Indium–Labeled Diethylenetriaminepentaacetic Acid Antibody

Free
Frank G. van Schaijk, Egbert Oosterwijk, Annemieke C. Soede, Matthias Broekema, Cathelijne Frielink, William J. McBride, David M. Goldenberg, Frans H.M. Corstens, Otto C. Boerman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7130s–7136s.
https://doi.org/10.1158/1078-0432.CCR-1004-0006
Published: 03 October 2005
View articletitled, Pretargeting of Carcinoembryonic Antigen–Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen × Anti-Indium–Labeled Diethylenetriaminepentaacetic Acid Antibody
Open the PDF for Pretargeting of Carcinoembryonic Antigen–Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen × Anti-Indium–Labeled Diethylenetriaminepentaacetic Acid Antibody in another window